Status:
UNKNOWN
The Microbiome of Pancreatic Cancer: "PANDEMIC" Study
Lead Sponsor:
Azienda Ospedaliera Universitaria Integrata Verona
Conditions:
Microbial Colonization
Pancreas Cancer
Eligibility:
All Genders
18-65 years
Brief Summary
Microbiome in patients affected by pancreatic ductal adenocarcinoma may present specific and identifiable patterns. These variations could affect the surgical outcome and increase the risk of life-thr...
Detailed Description
Pancreatic cancer is predicted to become the second leading cause of cancer-related death in the western world by 2030. Patients still have a poor prognosis, and a complete surgical resection provides...
Eligibility Criteria
Inclusion
- age between 18 and 65 years;
- PDAC lesion of the pancreatic head confirmed by preoperative histology or cytology;
- Scheduled for elective PD;
- ASA score \< 4
- The ability of the subject to understand the character and individual consequences of the clinical trial
- Written informed consent
Exclusion
- Patients with a degenerated pancreatic cyst lesion
- Neoadjuvant treatment (both radio and chemotherapy)
- Other current malignancies
- Antibiotic therapy during 4 weeks before surgery
- History of gastrointestinal tract resections or chronic gastrointestinal diseases
- Pregnant or breastfeeding patients
- Patients undergoing emergency surgery
- ASA score \> 4
- Impaired mental state or language problems
Key Trial Info
Start Date :
February 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04274972
Start Date
February 1 2020
End Date
December 31 2024
Last Update
January 17 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
AOUI Verona
Verona, Italy, 37124